Journal Mobile Options
Table of Contents
Vol. 49, No. 1, 2004
Issue release date: January 2004
Neuropsychobiology 2004;49:24–29

Psychobiological Aspects of Somatoform Disorders: Contributions of Monoaminergic Transmitter Systems

Rief W. · Pilger F. · Ihle D. · Verkerk R. · Scharpe S. · Maes M.
aCenter for Behavioral Medicine, Klinik Roseneck, Prien am Chiemsee, and bDepartment of Clinical Psychology and Psychotherapy, University of Marburg, Marburg, Germany; cDepartment of Medical Biochemistry, University of Antwerp, Edegem, Belgium; dDepartment of Psychiatry and Neuropsychology, University Hospital of Maastricht, Maastricht, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To evaluate the possible biological aspects of ‘unexplained physical symptoms’, this study examined serotonergic and noradrenergic monoamino acids in somatoform disorders and/or depression. Methods: Blood samples of 150 subjects from 4 groups (somatization syndrome; depression; depression and somatization; controls) were analyzed for amino acids contributing to the serotonergic and noradrenergic system and peripheral muscle energy balance (tryptophan, valine, leucine, isoleucine, phenylalanine and tyrosine). Results: Tryptophan, branched chain amino acids and other serotonergic amino acids were decreased in patients with somatoform symptoms, even when no depression was present. Conclusions: We conclude that serotonergic amino acids are biological correlates of multiple unexplained symptoms. Ways of action do not only involve brain mechanisms, but also energy metabolism in peripheral muscles.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kirmayer LJ, Robbins JM: Three forms of somatization in primary care: Prevalence, co-occurrence, and sociodemographic characteristics. J Nerv Ment Dis 1991;179:647–655.
  2. Kroenke K, Mangelsdorff D: Common symptoms in ambulatory care: Incidence, evaluation, therapy and outcome. Am J Med 1989;86:262–266.
  3. Escobar JI, Golding JM, Hough RL, Karno M, Burnam MA, Wells KB: Somatization in the community: Relationship to disability and use of services. Am J Public Health 1987;77:837–840.
  4. Rief W, Hessel A, Braehler E: Somatization symptoms and hypochondriacal features in the general population. Psychosom Med 2001;63:595–602.
  5. Rief W, Exner C: Psychobiology of somatoform disorders; in D’haenen HAH, den Boer JA, Willner P (eds): Biological Psychiatry. New York, Wiley, 2002, vol 2, pp 1063–1078.
  6. Maes M, Verkerk R, Delmeire L, Van Gastel A, Van Hunsel F, Sharpe S: Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 2000;97:11–20.
  7. Rief W, Heuser J, Mayrhuber E, Stelzer I, Hiller W, Fichter MM: The classification of multiple somatoform symptoms. J Nerv Ment Dis 1996;184:680–687.
  8. Escobar JI, Rubio-Stipec M, Canino G, Karno M: Somatic symptoms index (SSI): A new and abridged somatization construct – Prevalence and epidemiological correlates in two large community samples. J Nerv Ment Dis 1989;177:140–146.
  9. Hiller W, Rief W, Fichter MM: Further evidence for a broader concept of somatization disorder using the Somatic Symptom Index (SSI). Psychosomatics 1995;36:285–294.
  10. Rief W, Hiller W: Toward empirically based criteria for somatoform disorders. J Psychosom Res 1999;46:507–518.
  11. Wittchen HU, Schramm E, Zaudig M, Unland H: SKID: Stukturiertes klinisches Interview für DSM-IV, Achse I, deutsche Version. Göttingen, Hogrefe, 1997.
  12. Hiller W, Zaudig M, Mombour W: International Diagnostic Check Lists for ICD-10 and DSM-IV. Bern, Huber, 1997.
  13. Beck AT, Ward CH, Medelson M, Mock F, Erbaugh F: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  14. Derogatis LR: Symptom Checklist-90-R. Administration, Scoring, and Procedures Manual, ed 3. Minneapolis, National Computer Systems, 1994.
  15. Rief W, Hiller W, Heuser J: SOMS – Das Screening für somatoforme Störungen. Manual zum Fragebogen. Bern, Huber, 1997.
  16. Sharpe M, Hawton K, Clements A, Cowen PJ: Increased brain serotonin function in men with chronic fatigue syndrome. BMJ 1997;315:164–165.
  17. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915–919.
  18. Basbaum AI, Jessell TM: The perception of pain; in Kandel ER, Schwartz JH, Jessell TM (eds): Principles of Neural Science, ed 4. New York, McGraw-Hill, 2000, pp 472–491.
  19. Vassallo CM, Feldman E, Peto T, Castell L, Sharpley AL, Cowen PJ: Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. Psychol Med 2001;31:585–591.
  20. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 1992;19:90–94.
  21. Sutoo D, Akiyama K: Regulation of brain function by exercise. Neurobiol Dis 2003;13:1–14.
  22. Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P: Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 1997;22:261–267.
  23. Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M: Immunological differences between patients with major depression and somatization syndrome. Psychiatry Research 2001;105:165–174.
  24. Rief W, Auer C: Cortisol and somatization. Biol Psychol 2000;53:13–23.
  25. Song C, Lin A, Bonaccorso S, et al: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998;49:211–219.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50